Person: ZARİFOĞLU, MEHMET
Loading...
Email Address
Birth Date
20 results
Search Results
Now showing 1 - 10 of 20
Publication Can ID MigraineTM be used as a screening test for adolescent migraine?(Blackwell Publishing, 2008-04-01) Zarifoğlu, Mehmet; Karlı, Necdet; Taşkapılıoğlu, Özlem; ZARİFOĞLU, MEHMET; KARLI, HAMDİ NECDET; Taşkapılıoğlu, Özlem; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0003-4436-3797; AAK-6623-2020; EHN-5825-2022; JDE-9380-2023Publication Our cases of secondary narcolepsy with three different etiology: Review of the literature(Galenos Yayınevi, 2015-09-01) Savrun, Yusuf; Demir, Aylin Bican; Sıvacı, Ali Özhan; Bora, İbrahim; Zarifoğlu, Mehmet; Savrun, Yusuf; BİCAN DEMİR, AYLİN; Sıvacı, Ali Özhan; ZARİFOĞLU, MEHMET; BORA, İBRAHİM HAKKI; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0001-6739-8605; 0000-0002-9697-9510; FUS-0738-2022; KHB-9765-2024; GCS-6691-2022; ENI-7759-2022; EHN-5825-2022Narcolepsy is neurological disorder classified among central hypersomnolences group and characterized by excessive daytime sleepiness, cataplexy, associated symptoms like hypnogogic/hypnopompic hallucinations and sleep paralysis. It is divided into two types on the basis of accompanying cataplexy. In the pathophysiology of this disorder, which is accused an autoimmune process, hypocretin deficiency in the hypothalamus was shown. Narcolepsy is often seen as a primary disease in young population but may also occur with other disorders like cerebrovascular diseases, intracranial tumors, encephalitis, sarcoidosis, multiple sclerosis or after head trauma, infections, and vaccines; in which the disease is accepted as secondary narcolepsy. In this case report, patients presenting with excessive daytime sleepiness and diagnosed as having secondary narcolepsy due to medical causes, and who have Parkinson's disease (PD), history of interferon use and hypothalamic involvement associated with Langerhans cell histiocytosis (LCH) were reported. Daytime sleepiness complaints should be well questioned in organic pathologies related with hypothalamus-pituitary system such as PD and similar diseases or in patients with history of drug use and secondary narcolepsy should be beared in mind.Publication The role of obstructive sleep apnea syndrome as a cause of stroke(Galenos Publ House, 2015-09-01) SARIDAŞ, FURKAN; BİCAN DEMİR, AYLİN; Demir, Aylin Bican; Zarifoğlu, Mehmet; ZARİFOĞLU, MEHMET; Bora, İbrahim; BORA, İBRAHİM HAKKI; 0000-0001-5945-2317; 0000-0001-6739-8605; JCE-6657-2023; HSB-2700-2023; V-7170-2017Obstructive sleep apnea syndrome (OSAS) is a highly prevalent sleep disorder. Stroke is the second leading cause of death and the third leading cause of disability in the world. OSAS and stroke has common risk factors, are associated with each other and are both reported to play an important role in the etiology of each other. OSAS and stroke association was identified in our two cases in whom sleep-related respiratory problems were encountered before stroke. We would like to draw attention to the importance of OSAS being among the risk factors in the etiopathogenesis of stroke.Publication Association of brain volume and cognition in the chronic and episodic migraine patients(Sage Publications, 2013-06-01) Zarifoğlu, Mehmet; Şener, D. K.; Karlı, Nejdet; Hakyemez, Bahattin; Taşkapılıoğlu, Özlem; Özbek, Sevda Erer; Bakar, Mustafa; ZARİFOĞLU, MEHMET; Şener, D. K.; KARLI, HAMDİ NECDET; HAKYEMEZ, BAHATTİN; Taşkapılıoğlu, Özlem; ERER ÖZBEK, ÇİĞDEM SEVDA; BAKAR, HACI MUSTAFA; Tıp Fakültesi; Nöroloji Bölümü; 0000-0003-4436-3797; AAI-2318-2021; AAK-6623-2020; EHN-5825-2022; IOZ-7564-2023; CXD-7623-2022; DLN-1836-2022; EKN-8251-2022Publication Insight into pain syndromes in acute phase of mild-to-moderate covid-19: Frequency, clinical characteristics, and associated factors(Wiley, 2021-10-26) Karli, Necdet; KARLI, HAMDİ NECDET; Gullu, Gizem; GÜLLÜ, GİZEM; Kilic, Erhan; KILIÇ, ERHAN; Dinc, Yasemin; DİNÇ, YASEMİN; Ursavas, Ahmet; URSAVAŞ, AHMET; Yilmaz, Emel; YILMAZ, EMEL; Zarifoglu, Mehmet; ZARİFOĞLU, MEHMET; Tıp Fakültesi; 0000-0002-3894-1231; IUQ-6999-2023; AAI-3169-2021; IZQ-0662-2023; AAD-1271-2019Background Pain has been frequently described as a clinical feature of COVID-19, and the main pain syndromes that have been associated with the acute phase of this disease so far are headache, myalgia, arthralgia, and neuropathic pain. Understanding the characteristics of pain symptoms is crucial for a better clinical approach. Methods Patients who were diagnosed as having COVID-19 using reverse transcription-polymerase chain reaction were included in the study. Patients were asked to complete a 51-item questionnaire via a phone interview, which included questions on demographics, acute COVID-19 symptoms, the presence of pain symptoms, and their characteristics in the acute phase of COVID-19. Results A total of 222 out of 266 patients with COVID-19 participated in the study, yielding a response rate of 83.5%. A total of 159 patients reported at least one kind of pain syndrome with a prevalence of 71.6%. Myalgia was reported in 110 (49.6%) patients, headache in 109 (49.1%), neuropathic pain symptoms in 55 (24.8%), and polyarthralgia in 30 (13.5%) patients. A total of 66 patients reported only one type of pain, 46 reported two types, 42 reported three types, and five patients reported all four types of pain. Logistic regression analysis showed that there were significant associations between these pain syndromes and a strong association was found between neuropathic pain and headache. Conclusion Pain is a frequently observed symptom of mild-to-moderate COVID-19. There are significant relationships between pain syndromes in COVID-19, which may be due to a sequence of common etiologic factors. Significance This study described the main pain syndromes associated acute phase of mild-to-moderate COVID-19 and its associated features. Headaches and pain of neuropathic characteristics were prevalent in this sample.Publication Burden of headache(Sage Publications Ltd, 2008-04-01) Zarifoğlu, Mehmet; ZARİFOĞLU, MEHMET; Tıp Fakültesi; Noroloji Ana Bilim Dalı; EHN-5825-2022Publication Evaluation of the effects of botulinum toxin therapy on the clinical characteristics of pain and pain threshold value in patients with primary cervical dystonia(Journal Neurological Sciences, 2015-01-01) Özbek, Sevda Erer; Karlı Necdet; Yurtoğulları, Şükran; Zarifoğlu, Mehmet; Ocakoğlu, Gökhan; ERER ÖZBEK, ÇİĞDEM SEVDA; KARLI, HAMDİ NECDET; YURTOĞULLARI, ŞÜKRAN; ZARİFOĞLU, MEHMET; OCAKOĞLU, GÖKHANObjective: In 70% of patients with cervical dystonia (CD), the clinical presentation includes the symptom of pain. In this study, we aimed to define the types and clinical characteristics of the pain and to investigate whether this pain is a result of central sensitization by evaluating pre- and post-botulinum toxin (BoNT) treatment pain threshold values using electrical stimulation.Methods: The study enrolled a total of 35 patients with CD who received BoNT therapy. The patients were evaluated using the pain evaluation scale and Unified Dystonia Rating scale (UDRS) before and after BoNT therapy. The pain threshold values obtained from dystonic muscles, the contiguous or contralateral muscle without dystonic activity and a normal reference muscle with distant localization were recorded through electrical stimulation with EMG guidance, and all values obtained before and after BoNT therapy were compared.Results: No difference was found between the pain threshold values obtained from dystonic muscles before and after treatment. While no difference was observed across genders or VAS groups in terms of pain threshold values, the UDRS (duration and motor severity factor) scores showed significant decreases after treatment with BoNT in patients with painful dystonia and in patients with painless dystonia.Conclusions: The absence of a difference in pre- and post-BoNT treatment pain threshold values in dystonic muscles might be explained by the absence of central sensitization. Pain relief in dystonic patients might occur secondary to decreases in dystonic muscle contractions.Publication Migraine and E-TTH: Do they have similar clinical features and pathophysiologic mechanisms?(Blackwell Publishing Ltd, 2003-09-01) Karlı, Necdet; Zarifoğlu, Mehmet; Çalışkan, Nalan; KARLI, HAMDİ NECDET; ZARİFOĞLU, MEHMET; Çalışkan, Nalan; Tıp Fakültesi; Nöroloji Bölümü; JDE-9380-2023; EHN-5825-2022; EOX-5138-2022Publication The role of the dopamine β-hydroxylase functional polymorphism in patients with early-onset parkinson's disease in the Turkish population(Turkish Neurological Soc, 2021-03-01) Erer, Sevda; Eryılmaz, Işıl Ezgi; Çolak, Dilara Kamer; Egeli, Ünal; Çeçener, Gülşah; Tunca, Berrin; Karakuş, Ece; Çolakoğlu, Beril; Tokçaer, Ayşe Bora; Saka, Esen; Demirkıran, Meltem; Akbostancı, Cenk; Zarifoğlu, Mehmet; Doğu, Okan; Kaleagasi, Hakan; Kenangil, Gülay; Çakmur, Raif; Elibol, Bülent; ERER ÖZBEK, ÇİĞDEM SEVDA; ERYILMAZ, IŞIL EZGİ; Çolak, Dilara Kamer; EGELİ, ÜNAL; ÇEÇENER, GÜLŞAH; TUNCA, BERRİN; Karakuş, Ece; ZARİFOĞLU, MEHMET; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0001-7904-883X; 0000-0002-3316-316X; 0000-0002-2274-3230; 0000-0003-4968-2826; 0000-0002-3820-424X; 0000-0002-1619-6680; 0000-0003-2982-0961; GWV-3548-2022; AAH-1420-2021; DVY-9744-2022; JIP-4494-2023; AAP-9988-2020; ABI-6078-2020; FDA-2023-2022; EHN-5825-2022Objective: A functional single nucleotide polymorphism, rs1611115, in the dopamine beta-hydroxylase (DBH) gene, is reported to regulate plasma enzyme activity levels. Mere, we report the first evaluation of this association in patients with early-onset Parkinson's disease (EOPD) and healthy controls in the Turkish population.Materials and Methods: We evaluated the DBH rs1611115 polymorphism in 114 (64 male and 50 female) Turkish patients with EOPD and 58 sex- and age-matched healthy controls from the Turkish population. A total of 27.2% (n=31) of our patients who had any variation including pathogenic or non-pathogenic missense, non-sense and/or intronic variation with unknown significance in EOPD genes were grouped as "variation-positive EOPD". A total of 50.8% (n=58) of our patients were grouped as "variation and family history-negative EOPD" and the possible contribution of the DBH rs1611115 polymorphism to EOPD pathogenesis was evaluated in this group.Results: There was no significant difference in the genotypic and allelic frequencies of DBH rs1611115 between patients with EOPD and controls. To our knowledge, this is the first evaluation of the DBH rs1611115 polymorphism in patients with EOPD and ethnically matched controls in the Turkish population.Conclusion: Some previous studies have reported conflicting association results between DBH rs1611115 polymorphism and PD pathogenesis in different ethnic groups. Therefore, further studies are needed to evaluate dopamine metabolism-related generic variants and to determine their possible roles in EOPD susceptibility in the Turkish population.Publication A population-based survey to determine the prevalence of movement disorders in Orhangazi district of Bursa, Turkey(Galenos Yayıncılık, 2009-01-01) Özbek, Sevda Erer; Zarifoğlu, Mehmet; Karlı, Necdet; Özçakir, Alis; Yıldız, Demet; Aslan, Doğa; ERER ÖZBEK, ÇİĞDEM SEVDA; ZARİFOĞLU, MEHMET; KARLI, HAMDİ NECDET; ÖZÇAKIR, ALİS; Yıldız, Demet; Aslan, Doğa; Tıp Fakültesi; Aile Hekimliği Ana Bilim Dalı; 0000-0001-5588-2037; AAG-8209-2021; JGR-7854-2023; EHN-5825-2022; JDE-9380-2023; CIX-2047-2022; ELJ-9790-2022Objective: In this study we aimed to determine the prevalence of movement disorders among 40 years and older population in Orhangazi district of Bursa, Turkey.Patients and Methods: This population-based study was planned in three phases. In phase I, door-to-door home interviews were performed on 1256 subjects by residents of departments of neurology and family medicine by using a short questionnaire and 404 subjects with suspected symptoms of movement disorders and Parkinsonism were detected. These subjects were examined and videotaped in phase II. Of the suspected subjects in phase I, 131 did not attend to phase II for various reasons. In phase II, subjects were evaluated by movement disorders specialists by using scales specific to tremor, restless leg syndrome, Parkinson disease, and hemi-facial spasm. In phase III, video recording of all identified patients were reviewed and final diagnoses were made with a consensus of all three specialists.Results: In this phase, subjects were diagnosed to have restless leg syndrome n=60, 9.71%, essential tremor n=21, 3.34%, enhanced physhological tremor n=26, 4.14%, Parkinson's disease n= 14, 2.23%, hemifacial spasm n= 4, 0.82%, and dystonia n= 2, 0.41%.Conclusion: Although essential tremor has been reported as the most common movement disorder, in our study restless leg syndrome had higher prevalence than essential tremor.